Limits...
Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.

Mise N, Takami M, Suzuki A, Kamata T, Harada K, Hishiki T, Saito T, Terui K, Mitsunaga T, Nakata M, Ikeuchi T, Nakayama T, Yoshida H, Motohashi S - Cancer Sci. (2016)

Bottom Line: For further improvement in patient outcomes, ways to maximize the cytotoxic effects of anti-GD2 therapies with minimal toxicity are required.Although some of the expanded iNKT cells expressed natural killer (NK) cell markers, including FcγR, iNKT cells were not directly associated with ADCC.In conclusion, iNKT cell-based immunotherapy could be an appropriate candidate for anti-GD2 antibody therapy for neuroblastoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH

Related in: MedlinePlus

The expression of CD1d and GD2 on neuroblastoma (NB) cell lines. (a) The surface CD1d expression levels of various NB cell lines are shown. (b) The CD1d expression levels of cell lines from hematological malignancies are shown as positive controls. (c) The GD2 expression levels of various NB cell lines are shown. Shaded histograms represent isotype controls.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814252&req=5

cas12882-fig-0001: The expression of CD1d and GD2 on neuroblastoma (NB) cell lines. (a) The surface CD1d expression levels of various NB cell lines are shown. (b) The CD1d expression levels of cell lines from hematological malignancies are shown as positive controls. (c) The GD2 expression levels of various NB cell lines are shown. Shaded histograms represent isotype controls.

Mentions: As the activation of iNKT cells is CD1d restricted, the CD1d expression of several NB cell lines was first examined by flow cytometry. As previously described,23 CD1d was expressed on hematopoietic cells, such as Jurkat and THP‐1 cells (Fig. 1b), but it was not expressed on the surface of NB cell lines (Fig. 1a).


Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.

Mise N, Takami M, Suzuki A, Kamata T, Harada K, Hishiki T, Saito T, Terui K, Mitsunaga T, Nakata M, Ikeuchi T, Nakayama T, Yoshida H, Motohashi S - Cancer Sci. (2016)

The expression of CD1d and GD2 on neuroblastoma (NB) cell lines. (a) The surface CD1d expression levels of various NB cell lines are shown. (b) The CD1d expression levels of cell lines from hematological malignancies are shown as positive controls. (c) The GD2 expression levels of various NB cell lines are shown. Shaded histograms represent isotype controls.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814252&req=5

cas12882-fig-0001: The expression of CD1d and GD2 on neuroblastoma (NB) cell lines. (a) The surface CD1d expression levels of various NB cell lines are shown. (b) The CD1d expression levels of cell lines from hematological malignancies are shown as positive controls. (c) The GD2 expression levels of various NB cell lines are shown. Shaded histograms represent isotype controls.
Mentions: As the activation of iNKT cells is CD1d restricted, the CD1d expression of several NB cell lines was first examined by flow cytometry. As previously described,23 CD1d was expressed on hematopoietic cells, such as Jurkat and THP‐1 cells (Fig. 1b), but it was not expressed on the surface of NB cell lines (Fig. 1a).

Bottom Line: For further improvement in patient outcomes, ways to maximize the cytotoxic effects of anti-GD2 therapies with minimal toxicity are required.Although some of the expanded iNKT cells expressed natural killer (NK) cell markers, including FcγR, iNKT cells were not directly associated with ADCC.In conclusion, iNKT cell-based immunotherapy could be an appropriate candidate for anti-GD2 antibody therapy for neuroblastoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH
Related in: MedlinePlus